Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Unknown 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1

Conditions

Sarcoma 17Small Cell Lung Carcinoma 1Sarcoma, Synovial 1Sarcoma, Ewing 1Sarcoma, Alveolar Soft Part 1Osteosarcoma 1Neoplasm Metastasis 1Leiomyosarcoma 1Histiocytoma, Malignant Fibrous 1Gastrointestinal Stromal Tumors 1Desmoid Tumors 1Carcinoma, Non-Small-Cell Lung 1Bone Neoplasms 1

Interventions

Cyclophosphamide 25Temozolomide 22Vincristine 18Irinotecan 18Doxorubicin 13Topotecan 10Melphalan 10Etoposide 10Ifosfamide 8Busulfan 8cabozantinib 7Magnetic Resonance Spectroscopy 7Granulocyte Colony-Stimulating Factor 7Filgrastim 6regorafenib 5fludarabine 5X-Rays 5Specimen Handling 5Sirolimus 5Radiotherapy 5Gemcitabine 5Drug Therapy 5pegfilgrastim 4palbociclib 4liposomal doxorubicin 4irinotecan sucrosofate 4ganitumab 4fludarabine phosphate 4Trabectedin 4Phantoms, Imaging 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Sarcoma, Ewing × anlotinib × Sarcoma × Clear all
NCT03416517 2019-02-15

Anlotinib and Irinotecan for Ewing Sarcoma

Peking University People's Hospital

Phase 1/2 Unknown
47 enrolled
Sarcoma

Neoplasm Metastasis, Sarcoma, Ewing

Data powered by HemOnc (CC BY 4.0) Colophon âš¡